TI
TCON

Telemetry Investments’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Telemetry Investments’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$145K Hold
4,850
– – 0.23% 82
2022
Q3 		$162K Sell
4,850
-150
-3% -$5.73K 0.21% 106
2022
Q2 		$200K Buy
5,000
+1,650
+49% +$63.9K 0.24% 104
2022
Q1 		$176K Sell
3,350
-275
-8% -$13.8K 0.28% 97
2021
Q4 		$201K Sell
3,625
-2,900
-44% -$185K 0.26% 116
2021
Q3 		$505K Buy
6,525
+4,525
+226% +$383K 0.68% 47
2021
Q2 		$260K Buy
+2,000
New +$277K 0.36% 83
2021
Q1 		– Sell
-511
Closed -$120K – 143
2020
Q4 		$120K Sell
511
-2,225
-81% -$310K 0.2% 88
2020
Q3 		$283K Sell
2,736
-3,534
-56% -$189K 0.61% 56
2020
Q2 		$246K Buy
6,270
+2,950
+89% +$117K 0.67% 50
2020
Q1 		$111K Sell
3,320
-75
-2% -$4.36K 0.39% 46
2019
Q4 		$159K Sell
3,395
-194
-5% -$12.7K 0.53% 36
2019
Q3 		$321K Buy
3,589
+151
+4% +$15.5K 0.93% 31
2019
Q2 		$468K Buy
3,438
+477
+16% +$75.4K 0.36% 46
2019
Q1 		$811K Sell
2,961
-1,874
-39% -$406K 0.41% 34
2018
Q4 		$609K Buy
4,835
+2,928
+154% +$795K 0.39% 63
2018
Q3 		$782K Sell
1,907
-351
-16% -$162K 0.35% 47
2018
Q2 		$1.22M Buy
+2,258
New +$1.2M 0.46% 34

Other funds holding TCON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Telemetry Investments's TCON Position: Q4 2022 in Review

Telemetry Investments held its TRACON Pharmaceuticals, Inc. Common Stock (TCON) position steady in Q4 2022 at 4,850 shares worth $145K. The position accounts for 0.23% of the portfolio, ranked #82.

Telemetry Investments first reported a position in TCON in Q2 2018 and has held it in 18 quarters since. The position peaked at $1.22M in Q2 2018. 31 funds tracked by Wall St. Rank hold TCON as of Q4 2022.

  • Telemetry Investments held 4,850 shares of TRACON Pharmaceuticals, Inc. Common Stock worth $145K as of Q4 2022.
  • Telemetry Investments left its TRACON Pharmaceuticals, Inc. Common Stock share count unchanged in Q4 2022.
  • TRACON Pharmaceuticals, Inc. Common Stock made up 0.23% of Telemetry Investments's portfolio in Q4 2022, its #82 holding.
  • Telemetry Investments first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2018 and has held it in 18 quarters since.
  • Telemetry Investments's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $1.22M in Q2 2018.
  • 31 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Telemetry Investments's 13F filing for Q4 2022, filed 14 Feb 2023.